Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been assigned an average recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $10.6667.

A number of analysts recently commented on TSHA shares. Chardan Capital reiterated a “buy” rating and issued a $12.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Monday, December 29th. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price target on shares of Taysha Gene Therapies in a report on Friday, October 17th. Raymond James Financial reiterated a “strong-buy” rating and set a $13.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, January 6th. Finally, JMP Securities set a $8.00 price objective on Taysha Gene Therapies in a research note on Wednesday, November 5th.

Insiders Place Their Bets

In other news, insider Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies stock in a transaction on Monday, December 1st. The stock was sold at an average price of $4.51, for a total transaction of $1,172,811.97. Following the transaction, the insider owned 1,006,439 shares in the company, valued at approximately $4,539,039.89. The trade was a 20.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Sean P. Nolan sold 136,789 shares of Taysha Gene Therapies stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $4.75, for a total value of $649,747.75. Following the transaction, the chief executive officer directly owned 2,949,569 shares in the company, valued at approximately $14,010,452.75. This trade represents a 4.43% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 967,140 shares of company stock worth $4,510,613. Corporate insiders own 3.78% of the company’s stock.

Hedge Funds Weigh In On Taysha Gene Therapies

Several hedge funds have recently bought and sold shares of TSHA. ST Germain D J Co. Inc. raised its holdings in Taysha Gene Therapies by 81.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after acquiring an additional 4,333 shares during the period. Oppenheimer Asset Management Inc. bought a new stake in Taysha Gene Therapies during the fourth quarter valued at about $59,000. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new stake in shares of Taysha Gene Therapies in the third quarter valued at about $40,000. Marex Group plc bought a new position in shares of Taysha Gene Therapies in the second quarter worth about $29,000. Finally, E Fund Management Co. Ltd. bought a new position in shares of Taysha Gene Therapies in the second quarter worth about $31,000. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Price Performance

Shares of TSHA opened at $4.72 on Friday. The stock’s fifty day moving average is $5.13 and its 200-day moving average is $4.16. The firm has a market capitalization of $1.29 billion, a price-to-earnings ratio of -14.30 and a beta of 1.01. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.48 and a current ratio of 10.48. Taysha Gene Therapies has a one year low of $1.05 and a one year high of $6.02.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, hitting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. Equities analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.